FDA Seeks To Cut Abbott Synthroid Distribution To 60% By August 2002

An FDA guidance on levothyroxine products calls for Abbott to reduce Synthroid distribution to 60% of current levels by August 2002, about the time the company anticipates FDA approval for the drug.